Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com under the investor webcast section and will be archived for future reference. To listen to the conference call, please dial (800) 447-0521 (US/Canada) or (847) 413-3238 (International) and use the participant code "28602165" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients with diabetes and by healthcare providers in the hospital.Cautionary Statement Regarding Forward Looking Statements DexCom is a medical device company with a limited operating history. Successful commercialization and sale of the company’s products is subject to numerous risks and uncertainties, including product performance, a lack of acceptance in the marketplace by physicians and patients, the company’s inability to manufacture products in commercial quantities at an acceptable cost and quality level, possible delays in the company’s development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ended September 30, 2011, as filed with the Securities and Exchange Commission on November 2, 2011.
|Consolidated Balance Sheets|
|(In thousands—except par value data)|
|September 30, 2011 (Unaudited)||December 31, 2010|
|Cash and cash equivalents||$||17,523||$||4,889|
|Short-term marketable securities, available-for-sale||79,794||42,224|
|Accounts receivable, net||9,003||6,671|
|Prepaid and other current assets||2,457||2,690|
|Total current assets||115,232||65,361|
|Property and equipment, net||12,524||10,763|
|Liabilities and stockholders’ equity|
|Accounts payable and accrued liabilities||$||6,045||$||5,350|
|Accrued payroll and related expenses||6,961||5,730|
|Current portion of long-term debt||0||525|
|Current portion of deferred revenue||1,737||3,524|
|Total current liabilities||14,743||15,129|
|Commitments and contingencies|
|Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively||0||0|
|Common stock, $0.001 par value, 100,000 authorized; 67,783 and 67,500 issued and outstanding, respectively, at September 30, 2011; and 62,360 and 62,078 shares issued and outstanding, respectively, at December 31, 2010||68||62|
|Additional paid-in capital||491,964||407,375|
|Accumulated other comprehensive loss||(94||)||(66||)|
|Total stockholders’ equity||113,065||60,993|
|Total liabilities and stockholders’ equity||$||128,793||$||77,164|
|Consolidated Statements of Operations|
|(In thousands—except per share data)|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Development grant and other revenue||1,598||888||8,871||6,412|
|Product cost of sales||9,230||6,982||25,933||18,440|
|Development and other cost of sales||860||1,206||2,761||3,101|
|Total cost of sales||10,090||8,188||28,694||21,541|
|Research and development||8,231||6,161||21,515||16,325|
|Selling, general and administrative||13,241||10,377||36,203||30,533|
|Total operating expenses||21,472||16,538||57,718||46,858|
|Loss on debt extinguishment upon conversion of convertible debt||0||(312||)||0||(8,487||)|
|Basic and diluted net loss per share||$||(0.20||)||$||(0.23||)||$||(0.50||)||$||(0.81||)|
|Shares used to compute basic and diluted net loss per share||67,397||58,200||64,910||55,707|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV